RxDoctor Payments Data

Melyssa Mosley

Nurse Practitioner · Davenport, IANPI 1194232850

Payments from drug & device makers

$998in general payments, 2019–2025

Across 55 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$496
  • Novartis$92
  • Axsome Therapeutics, Inc.$51
  • Lilly USA, LLC$41
  • Biogen$40
  • Neurocrine Biosciences, Inc.$38
  • plus $241 from 10 others

What the payments were for

  • Food & beverage$998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$998 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$59,135
Medicare patients
287
Services billed
730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate14$71,943
UbrelvyUbrogepant46$69,049
Aimovig AutoinjectorErenumab-Aooe59$43,560
QuliptaAtogepant39$42,505
Emgality PenGalcanezumab-Gnlm31$21,561
Nurtec OdtRimegepant Sulfate16$16,009
Memantine Hcl232$6,111
RivastigmineRivastigmine Tartrate76$5,204
Carbidopa-LevodopaCarbidopa/Levodopa202$5,106
Gabapentin227$4,214
Donepezil Hcl540$3,946
Pregabalin139$3,058
Levetiracetam130$2,486
Carbidopa-Levodopa ErCarbidopa/Levodopa60$2,054
Atropine Sulfate13$1,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$496$111,55485 claims
PfizerNurtec Odt$26$16,00916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →